Novartis moves to buy Speedel
This article was originally published in Scrip
Novartishas taken a major step towards acquiring its fellow Swiss company Speedel. It has purchased an additional 51.7% of shares in the company, bringing the total amount of shares owned by Novartis to 61.4%. Novartis, which bought the shares for CHF130 ($126) each, will now begin a mandatory tender offer to acquire the remaining shares at the same price, and expects the full acquisition to cost CHF907 million.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.